© 2000 European Society of Cardiology
Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan
a Department of Cardiology, Marienhospital Josef-Albers-Strasse 70, D 46236 Bottrop, Germany
b University of Witten/Herdecke Germany
* Corresponding author. Fax: +49-2041-1061409.
 |
Abstract |
|---|
Background: The efficacy of ACE-inhibitor therapy is well documented in the treatment of chronic heart failure. As pharmacological mechanisms of ACE-inhibition and angiotensin II AT1-receptor-antagonists differ, an additional positive effect concerning left ventricular function can be expected in combining both classes of drugs.
Methods: Twenty patients (64.9 ± 8.5 years) with advanced chronic heart failure (NYHA class III) receiving long-term medication with digitalis, diuretics and ACE-inhibitors were randomized to either eprosartan (540 ± 96 mg/day) or placebo, according to a blinded protocol. Hemodynamic measurements by impedance cardiography were performed at baseline and after 8.85 ± 1.5 days of study medication treatment.
Results: Additional treatment with eprosartan resulted in a higher cardiac output than in the control group (P < 0.05). While in the active treatment group cardiac output increased significantly from baseline (2.27–3.24 l/min, P = 0.039), there was no change in the control group.
Conclusions: The additional treatment with the AT1-receptor antagonist eprosartan, given to severe heart failure patients, who received digitalis, diuretics and ACE-inhibitors, resulted in a beneficial effect by increasing cardiac output. This effect may be due to eprosartan's additional property of blocking the autocrine interaction of locally and not ACE-generated angiotensin II with their respective vascular and myocardial AT1-receptors as well as the influence on prejunctional AT1-receptors located on sympathetic nerve terminals.
Key Words: ACE-inhibitors • Selective angiotensin II AT1-receptor-antagonist • Chronic heart failure • Norepinephrine • Eprosartan
Received March 4, 1999; Revised September 23, 1999; Accepted January 7, 2000
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. S. Bedair, T. Karthikeyan, A. Quintero, Y. Li, and J. Huard Angiotensin II Receptor Blockade Administered After Injury Improves Muscle Regeneration and Decreases Fibrosis in Normal Skeletal Muscle Am. J. Sports Med., August 1, 2008; 36(8): 1548 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Sica Review: The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 66 - 71. [Abstract] [PDF]
|
|
|
|
 |
|
 F. C. Barone, R. W. Coatney, S. Chandra, S. K. Sarkar, A. H. Nelson, L. C. Contino, D. P. Brooks, W. G. Campbell Jr., E. H. Ohlstein, and R. N. Willette Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats Cardiovasc Res, June 1, 2001; 50(3): 525 - 537. [Abstract] [Full Text] [PDF]
|
|